SCHEMBL4742375

SCHEMBL4742375

COc1ccc2cc(CNCc3ccc(C(F)(F)F)cc3)c(Oc3cccnc3)nc2c1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GPBAR1 Q8TDU6 8/20 0.47
PPARD Q03181 1/20 0.42
DGAT2 Q96PD7 1/20 0.40
CYP2C9 P11712 2/20 0.40
CYP19A1 P11511 1/20 0.40
CYP11B1 P15538 1/20 0.40
CYP11B2 P19099 1/20 0.40
CYP3A4 P08684 2/20 0.40
KDM4E B2RXH2 2/20 0.40
ALDH1A1 P00352 2/20 0.40
GLA P06280 1/20 0.40
POLB P06746 1/20 0.40
GAA P10253 1/20 0.40
RAB9A P51151 1/20 0.40
MEN1 O00255 1/20 0.39
KMT2A Q03164 1/20 0.39
ACP1 P24666 1/20 0.39
TACR3 P29371 1/20 0.39
CYP1A2 P05177 1/20 0.38
CYP2D6 P10635 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4743145 0.84 GPBAR1 (0.66) GPBAR1CYP2C9CYP19A1CYP11B1CYP11B2
SCHEMBL4878378 0.80 GPBAR1 (0.73) GPBAR1
SCHEMBL4743315 0.79 GPBAR1 (0.65) GPBAR1ACP1TACR3
SCHEMBL14106092 0.78 GPBAR1 (0.48) GPBAR1MEN1KMT2AACP1TACR3
SCHEMBL4785424 0.77 GPBAR1 (0.64) GPBAR1ACP1TACR3
SCHEMBL4741854 0.77 GPBAR1 (0.48) GPBAR1ALDH1A1MEN1KMT2AACP1
SCHEMBL4744687 0.76 GPBAR1 (0.55) GPBAR1CYP2C9CYP19A1CYP11B1CYP11B2
SCHEMBL4742305 0.75 GPBAR1 (0.54) GPBAR1CYP2C9CYP19A1CYP11B1CYP11B2
SCHEMBL4742051 0.75 GPBAR1 (0.66) GPBAR1DGAT2CYP2C9CYP19A1CYP11B1
SCHEMBL4878000 0.75 GPBAR1 (0.54) GPBAR1KDM4EALDH1A1ACP1TACR3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080221161-A1 HETEROCYCLIC MODULATORS OF TGR5 FOR TREATMENT OF DISEASE KALYPSYS, INC. (US) 2008-09-11 US disclosed
US-20080221161-A1 HETEROCYCLIC MODULATORS OF TGR5 FOR TREATMENT OF DISEASE KALYPSYS, INC. (US) 2008-09-11 US disclosed
US-20080221161-A1 HETEROCYCLIC MODULATORS OF TGR5 FOR TREATMENT OF DISEASE KALYPSYS, INC. (US) 2008-09-11 US disclosed
WO-2008097976-A1 HETEROCYCLIC MODULATORS OF TGR5 FOR TREATMENT OF DISEASE KALYPSYS, INC. (US) 2008-08-14 WO disclosed
WO-2008097976-A1 HETEROCYCLIC MODULATORS OF TGR5 FOR TREATMENT OF DISEASE KALYPSYS, INC. (US) 2008-08-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080221161-A1 HETEROCYCLIC MODULATORS OF TGR5 FOR TREATMENT OF DISEASE GPR119, GPBAR1, LDLR GPBAR1 2/4885PPARD 219/4885DGAT2 5/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.